Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31067

Spanish Menopause Society position statement: use of tibolone in postmenopausal women


no-thumbnailView/Open:

 Spanish Menopause Society position statement use of tibolone.pdf



226,75 kB
Adobe PDF
Share:

This resource is restricted

Title:
Spanish Menopause Society position statement: use of tibolone in postmenopausal women
Authors:
Mendoza, Nicolás
Abad, Pedro  
BARO, FRANCESC  
Cancelo, Maria Jesús
Llaneza, Plácido
Manubens, Montserrat
Quereda, Francisco  
Sánchez-Borrego, Rafael
Editor:
Lippincott, Williams & Wilkins
Department:
Departamentos de la UMH::Salud Pública, Historia de la Ciencia y Ginecología
Issue Date:
2012-10-25
URI:
https://hdl.handle.net/11000/31067
Abstract:
Tibolone is a drug with complex tissue-specific action that exhibits a combination of estrogenic, progestogenic, and slight androgenic activity. Its variable profile explains its clinical effects, depending on the target tissue where it is metabolized, its metabolites’ affinity for and potency in hormone receptors, and probable enzymatic activity modulation. In recent reviews and clinical trials, the effectiveness of tibolone in alleviating different hot flush menopause symptoms, mainly in mood and sexuality disorders, has been noted. In Spain, tibolone is the most prescribed hormonal treatment, and one of the most common complaints among postmenopausal women is change in sexual drive. For such reason, a panel of experts from the Spanish Menopause Society met to develop usage recommendations based on the best evidence available.
Keywords/Subjects:
Tibolone
Postmenopausal
Hormone therapy
Type of document:
application/pdf
Access rights:
info:eu-repo/semantics/closedAccess
DOI:
https://doi.org/10.1097/GME.0b013e31827b18c5
Appears in Collections:
Artículos Salud Pública, Historia de la Ciencia y Ginecología



Creative Commons ???jsp.display-item.text9???